Researchers Submit Patent Application, "Overexpression Of Lemd2, Lemd3, Or Chmp7 As A Therapeutic Modality For Tauopathy", for Approval (USPTO 20230293727).
In: Gene Therapy Weekly, 2023-10-09, S. 4420-4420
serialPeriodical
Zugriff:
In some such methods, the LEMD2, the CHMP7, or the LEMD3 or the nucleic acid encoding the LEMD2, the CHMP7, or the LEMD3 is administered to the subject via intraperitoneal injection. An expression construct comprising a nucleic acid encoding a LEM domain-containing protein 2 (LEMD2), a charged multivesicular body protein 7 (CHMP7), or an inner nuclear membrane protein Man 1 (LEMD3) operably linked to a heterologous promoter. The method of claim 12, wherein the LEMD3 is a human LEMD3, optionally wherein the LEMD3 comprises SEQ ID NO: 23, and optionally wherein the nucleic acid encoding the LEMD3 comprises SEQ ID NO: 24 or 25. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Overexpression Of Lemd2, Lemd3, Or Chmp7 As A Therapeutic Modality For Tauopathy", for Approval (USPTO 20230293727).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2023-10-09, S. 4420-4420 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|